Shares of Corvus Pharmaceuticals, Inc. (CRVS) are rallying over 100% in pre-market today, after the company announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.
from RTT - Before the Bell https://ift.tt/3iFVZOX
via IFTTT
No comments:
Post a Comment